Download Files:
Products Details
Product Description
– EGFR-IN-43 (Compound 17c) is a potent inhibitor of EGFR with single-digit nanomolar activity. EGFR-IN-43 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-43 retains both ER antagonist activity and EGFR inhibition. EGFR-IN-43 has superior anti-cancer activity[1].
Web ID
– HY-145824
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C50H55ClFN5O5
References
– [1]Abdelmalek CM, et al. Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer. J Med Chem. 2022;65(6):4616-4632.
Molecular Weight
– 860.45
SMILES
– ClC1=CC(NC2=C3C(C=C(OC)C(OCCCNC(CCCCCCN(CCOC4=CC=C(C=C4)/C(C5=CC=C(C=C5)O)=C(CC)C6=CC=CC=C6)C)=O)=C3)=NC=N2)=CC=C1F
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– EGFR
Pathway
– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
